Quarterly report pursuant to Section 13 or 15(d)

Royalty and Commercial Payment Purchase Agreements - Viracta (Details)

v3.23.2
Royalty and Commercial Payment Purchase Agreements - Viracta (Details)
$ in Thousands
6 Months Ended
Mar. 22, 2021
USD ($)
item
Jun. 30, 2023
USD ($)
Jun. 30, 2022
USD ($)
Dec. 31, 2022
USD ($)
Agreements        
Payments of consideration under RPAs, AAAs and CPPAs   $ 14,650 $ 5,000  
Long-term royalty and commercial payment receivables   72,232   $ 63,683
Viracta | Royalty Purchase Agreement        
Agreements        
Number of drug candidates | item 2      
Payments of consideration under RPAs, AAAs and CPPAs $ 13,500      
Maximum amount of potential milestones and other payments receivable 54,000      
Amount of maximum consideration retained 20,000      
Maximum amount of potential regulatory and commercial milestones receivable 57,000      
Long-term royalty and commercial payment receivables $ 13,500      
Amount of allowance for credit losses   $ 0   $ 0